Abelacimab: A Leap Forward in Anticoagulation with FXI and FXIa Inhibition

Overview

Journal Curr Res Pharmacol Drug Discov

Date 2024 Mar 28

PMID 38545505

Authors

Hisham A Badreldin

Nada Alsuhebany

Mohammed Alzahrani

Abdulmajeed M Alshehri

Maha Aldoughaim

Saleh Alqifari

Omar Yassin

Lama Alfehaid

Tariq Alqahtani

Affiliations

Soon will be listed here.

Abstract

Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased risk of gastrointestinal bleeding and unsuitability for patients with mechanical heart valves. Recent research has highlighted Factor XI (FXI) as a promising anticoagulation target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis. This review provides a comprehensive analysis of abelacimab, examining its clinical pharmacology and its pharmacokinetic and pharmacodynamic properties. It scrutinizes abelacimab's safety profile and key monitoring parameters. The current evidence supporting its use and potential future research strengthening its position in anticoagulant therapy is also discussed. The objective is to enhance understanding and contribute to discussions around developing safer anticoagulants, particularly for patients at risk for thrombosis.

References

Verhamme P, Yi B, Segers A, Salter J, Bloomfield D, Buller H . Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(7):609-617. DOI: 10.1056/NEJMoa2105872. View

Tillman B, Gailani D . Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces. Semin Thromb Hemost. 2017; 44(1):60-69. PMC: 5794506. DOI: 10.1055/s-0037-1603937. View

Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F . Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015; 21(4):496-501. DOI: 10.1111/hae.12628. View

Schmaier A . Physiologic activities of the contact activation system. Thromb Res. 2014; 133 Suppl 1:S41-4. PMC: 4004333. DOI: 10.1016/j.thromres.2014.03.018. View

Mohammed B, Matafonov A, Ivanov I, Sun M, Cheng Q, Dickeson S . An update on factor XI structure and function. Thromb Res. 2017; 161:94-105. PMC: 5776729. DOI: 10.1016/j.thromres.2017.10.008. View

Yi B, Freedholm D, Widener N, Wang X, Simard E, Cullen C . Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2021; 20(2):307-315. PMC: 9298689. DOI: 10.1111/jth.15577. View

Shi Y, Gauer J, Baker S, Philippou H, Connell S, Ariens R . Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro. Sci Rep. 2021; 11(1):1718. PMC: 7814028. DOI: 10.1038/s41598-021-81268-7. View

Franchini M, Liumbruno G, Bonfanti C, Lippi G . The evolution of anticoagulant therapy. Blood Transfus. 2015; 14(2):175-84. PMC: 4781787. DOI: 10.2450/2015.0096-15. View

Chen A, Stecker E, Warden B . Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020; 9(13):e017559. PMC: 7670541. DOI: 10.1161/JAHA.120.017559. View

10.

Salomon O, Steinberg D, Zucker M, Varon D, Zivelin A, Seligsohn U . Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2010; 105(2):269-73. DOI: 10.1160/TH10-05-0307. View

11.

Spiezia L, Forestan C, Campello E, Simion C, Simioni P . Persistently High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. J Clin Med. 2023; 12(15). PMC: 10420025. DOI: 10.3390/jcm12154890. View

12.

Julia S, James U . Direct Oral Anticoagulants: A Quick Guide. Eur Cardiol. 2018; 12(1):40-45. PMC: 6206466. DOI: 10.15420/ecr.2017:11:2. View

13.

Li T, Liu J, Wu W . Factor XI, a potential target for anticoagulation therapy for venous thromboembolism. Front Cardiovasc Med. 2022; 9:975767. PMC: 9659736. DOI: 10.3389/fcvm.2022.975767. View

14.

Campello E, Simioni P, Prandoni P, Ferri N . Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022; 11(21). PMC: 9654315. DOI: 10.3390/jcm11216314. View

15.

Wheeler A, Gailani D . Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016; 9(7):629-37. PMC: 4950943. DOI: 10.1080/17474086.2016.1191944. View

16.

Koch A, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y . MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019; 133(13):1507-1516. DOI: 10.1182/blood-2018-10-880849. View